By: Kelly K. Nichols, OD, MPH, PhD, FAAO, Moderator; Marc R. Bloomenstein, OD, FAAO; Douglas K. Devries, OD; Milton M. Hom, OD, FAAO; Walter O. Whitley, OD, MBA, FAAO
This course has expired. You can still review the content but course credit is no longer available.
ACTIVITY DESCRIPTION
Nearly 33% of patients in eye care clinics present with complaints about dry eye signs and symptoms. Clinicians remain challenged with both the diagnosis and best treatment options for dry eye disease (DED) because, to date, multiple causes of the disorder have been identified. Yet the proportion of US adults who reported having symptoms of DED seemed to plateau from 2015-2018, with about 41% noting occasional DED and 12% noting frequent DED. Extrapolating those figures to the US population equates to more than 135 million people with DED.
Supported through an educational grant from Kala Pharmaceuticals
Learning Objectives
Upon completion of this activity, the participant should be able to:
Evolve is an approved COPE Administrator.
This course is COPE approved for 1.0 hours of CE Credit for Optometrists.
COPE Course ID: 62389-AS
COPE Event ID: 117355
To Obtain Credit
To obtain credit for this activity, you must read the activity in its entirety and complete the Posttest/Activity Evaluation/Satisfaction Measures Form, which consists of a series of multiple choice questions.
Kelly Kinney Nichols, OD, MPH, PhD, FAAO and/or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan plc., Bruder Healthcare, Kala Pharmaceuticals, Olympic Ophthalmics, Oyster Point, Shire, Sun Pharmaceuticals, ScienceBased Health, Sight Sciences, Silk Technologies, and Topivert. Grant /Research Support: Alcon, Bruder Healthcare, Allergan plc., Kala Pharmaceuticals, Johnson and Johnson Vision Care, and TearSolutions.
Marc Bloomenstein, OD, and/or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan plc., Johnson and Johnson Vision, and Reichert. Speaker’s Bureau: Alcon, Allergan, plc., Bausch & Lomb, and Johnson and Johnson Vision. Stock/Shareholder: TearLab.
Milton M. Hom, OD, FAAO, and/or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Sun Pharmaceuticals. Grant/ Research Support: Allergan plc., Cooper Vision Surgical, Hovione, Kala Pharmaceuticals, Shire/Takeda, Tarsus, and Tear Solutions.
Walt Whitley, OD, MBA, and/or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Alcon, Allergan plc., Bausch & Lomb, BioTissue, Glaukos, Johnson and Johnson Vision, Ocusoft Science Based Health, Shire, Regeneron Pharmaceuticals and TearLab.
Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education, Susan Gallagher-Pecha, director of client services and project management, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
Off-Label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education, Modern Optometry, or Kala Pharmaceuticals.
